Diffuse large B cell lymphoma: How can we cure more patients in 2012?

Best Practice and Research: Clinical Haematology

Volumn 25, Issue 1, 2012, Pages 41-47

  Moskowitz, Craig ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cell or origin; diffuse large B cell lymphoma; double hit lymphoma; FDG PET

Indexed keywords

CARBOPLATIN; CD5 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HLA DR ANTIGEN; IFOSFAMIDE; KI 67 ANTIGEN; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM PROTEINS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84858315205     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2012.01.008     Document Type: Review

References (36)

1. M.A. Shipp Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood 83 5 1994 1165 1173 Epub 1994/03/01
2. L.H. Sehn, B. Berry, and M. Chhanabhai The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood 109 5 2007 1857 1861 Epub 2006/11/16 (Pubitemid 46348180)
3. B. Coiffier, E. Lepage, and J. Briere CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma The New England Journal of Medicine 346 4 2002 235 242 Epub 2002/01/25 (Pubitemid 34438862)
4. L. Colomo, A. Lopez-Guillermo, and M. Perales Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma Blood 101 1 2003 78 84 Epub 2002/10/24 (Pubitemid 36025890)
5. M. Taniguchi, K. Oka, and A. Hiasa De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation Blood 91 4 1998 1145 1151 Epub 1998/03/07 (Pubitemid 28086866)
6. M. Yamaguchi, M. Seto, and M. Okamoto De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients Blood 99 3 2002 815 821 Epub 2002/01/25 (Pubitemid 34525540)
7. G. Salles, D. de Jong, and W. Xie Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium Blood 117 26 2011 7070 7078 Epub 2011/05/04
8. C.H. Moskowitz, H. Schoder, and J. Teruya-Feldstein Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 28 11 2010 1896 1903 Epub 2010/03/10
9. A.A. Alizadeh, M.B. Eisen, and R.E. Davis Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 6769 2000 503 511 Epub 2000/02/17 (Pubitemid 30082188)
10. I.S. Lossos, D.K. Czerwinski, and A.A. Alizadeh Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes The New England Journal of Medicine 350 18 2004 1828 1837 Epub 2004/04/30 (Pubitemid 38917249)
11. C.P. Hans, D.D. Weisenburger, and T.C. Greiner Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103 1 2004 275 282 Epub 2003/09/25 (Pubitemid 38029949)
12. L.A. Honigberg, A.M. Smith, and M. Sirisawad The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proceedings of the National Academy of Sciences of the United States of America 107 29 2010 13075 13080 Epub 2010/07/10
13. S. Cheng, G. Coffey, and X.H. Zhang SYK inhibition and response prediction in diffuse large B-cell lymphoma Blood 118 24 2011 6342 6352 Epub 2011/10/26
14. K.J. Savage, N.A. Johnson, and S. Ben-Neriah MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy Blood 114 17 2009 3533 3537 Epub 2009/08/26
15. H. Schoder, and C. Moskowitz PET imaging for response assessment in lymphoma: potential and limitations Radiologic Clinics of North America 46 2 2008 225 241 viii. Epub 2008/07/16 (Pubitemid 351932048)
16. H. Schoder, M. Fury, and N. Lee PET monitoring of therapy response in head and neck squamous cell carcinoma Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 50 Suppl. 1 2009 74S 88S Epub 2009/04/22
17. C.H. Moskowitz, A. Zelenetz, and H. Schoder An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma Journal of the National Comprehensive Cancer Network: JNCCN 8 3 2010 347 352 Epub 2010/03/06
18. N.G. Mikhaeel Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now? Leukemia & Lymphoma 50 12 2009 1931 1936 Epub 2009/12/17
19. N.G. Mikhaeel, A.R. Timothy, and M.J. O'Doherty 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT Leukemia & Lymphoma 39 5-6 2000 543 553 Epub 2001/05/09 (Pubitemid 32162393)
20. C. Haioun, E. Itti, and A. Rahmouni [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome Blood 106 4 2005 1376 1381 Epub 2005/04/30 (Pubitemid 41129604)
21. A.F. Cashen, F. Dehdashti, and J. Luo 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 52 3 2011 386 392 Epub 2011/02/16
22. M. Meignan, E. Itti, and A. Gallamini Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation-where do we stand? Leukemia & Lymphoma 50 11 2009 1753 1756 Epub 2009/10/30
23. M. Meignan, C. Haioun, and E. Itti Value of [18F]fluorodeoxyglucose- positron emission tomography in managing patients with aggressive non-Hodgkin's lymphoma Clinical Lymphoma & Myeloma 6 4 2006 306 313 Epub 2006/03/02
24. C. Lin, E. Itti, and C. Haioun Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 48 10 2007 1626 1632 Epub 2007/09/18 (Pubitemid 47572710)
25. E. Itti, C. Lin, and J. Dupuis Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 50 4 2009 527 533 Epub 2009/03/18
26. R.O. Casasnovas, M. Meignan, and A. Berriolo-Riedinger SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma Blood 118 1 2011 37 43 Epub 2011/04/27
27. S.J. Horning, M.E. Juweid, and H. Schoder Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study Blood 115 4 2010 775 777 quiz 918. Epub 2009/09/22
28. T. Kewalramani, A.D. Zelenetz, and S.D. Nimer Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Blood 103 10 2004 3684 3688 Epub 2004/01/24 (Pubitemid 38596282)
29. S.M. Horwitz, R.S. Negrin, and K.G. Blume Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma Blood 103 3 2004 777 783 Epub 2003/08/09 (Pubitemid 38129532)
30. C. Gisselbrecht, B. Glass, and N. Mounier Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 28 27 2010 4184 4190 Epub 2010/07/28
31. M.J. Matasar, M.S. Czuczman, and M.A. Rodriguez A phase II study of ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory aggressive B-Cell lymphoma prior to Autologous Stem Cell Transplantation (ASCT) ASH San Diego 2011
32. T. Terasawa, I.J. Dahabreh, and T. Nihashi Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis The Oncologist 15 7 2010 750 759 Epub 2010/07/01
33. B.W. Schot, J.M. Zijlstra, and W.J. Sluiter Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma Blood 109 2 2007 486 491 Epub 2006/09/28 (Pubitemid 46105942)
34. J.E. Filmont, C. Gisselbrecht, and X. Cuenca The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation Cancer 110 6 2007 1361 1369 Epub 2007/07/12 (Pubitemid 47435610)
35. B.S. Hoppe, C.H. Moskowitz, and Z. Zhang The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma Bone Marrow Transplantation 43 12 2009 941 948 Epub 2009/01/14
36. A.J. Moskowitz, J. Yahalom, and T. Kewalramani Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma Blood 116 23 2010 4934 4937 Epub 2010/08/25